March 3, 2026Open Access

Clinical outcomes of immunocompromised patients administered tixagevimab–cilgavimab as pre-exposure prophylaxis for COVID-19: Real-world experience in Taiwan

Key Points

Immunocompromised patients treated with tixagevimab/cilgavimab showed low rates of severe COVID-19.
The findings suggest that monoclonal antibodies could effectively prevent COVID-19 severity.
Analysis of clinical outcomes highlights the efficacy of pre-exposure prophylaxis in vulnerable groups.
Ongoing research is essential to further explore the role of these antibodies in preventing COVID-19.

Abstract

Tixagevimab/cilgavimab -treated immunocompromised patients had a low rate of subsequent severe or critical COVID-19. Our study provides insights into the role of future monoclonal antibodies as COVID-19 pre-exposure prophylaxis among immunocompromised patients and emphasizes the need for ongoing research.

Bookmark

View Full Paper

Cite This Study

Ho et al. (Mon,) studied this question.

synapsesocial.com/papers/69a765d0badf0bb9e87da8b1 https://doi.org/https://doi.org/10.1016/j.ijid.2026.108455

Bookmark

View Full Paper